Comparative Pharmacology
Head-to-head clinical analysis: ARGATROBAN versus ARGATROBAN IN DEXTROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARGATROBAN versus ARGATROBAN IN DEXTROSE.
ARGATROBAN vs ARGATROBAN IN DEXTROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, XIII, and platelet aggregation.
Argatroban is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, XIII, and protein C, and platelet aggregation.
Initial dose: 2 mcg/kg/min IV continuous infusion; adjust to maintain aPTT 1.5-3 times baseline. For patients with HIT undergoing PCI: initial bolus 350 mcg/kg IV, then 25 mcg/kg/min IV infusion.
Initial bolus of 350 mcg/kg IV over 3-5 minutes, followed by continuous IV infusion at 25 mcg/kg/min for normal coagulation; titrate to aPTT 1.5-3 times baseline, not exceeding 100 seconds; typical infusion rate 2-10 mcg/kg/min.
None Documented
None Documented
Clinical Note
moderateArgatroban + Benzydamine
"Argatroban may increase the anticoagulant activities of Benzydamine."
Clinical Note
moderateArgatroban + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Argatroban."
Clinical Note
moderateArgatroban + Droxicam
"Argatroban may increase the anticoagulant activities of Droxicam."
Clinical Note
moderateArgatroban + Loxoprofen
Terminal half-life 39-51 minutes (dose-dependent); clinical context: continuous IV infusion required for stable anticoagulation.
Terminal elimination half-life is 39–51 minutes in healthy subjects; prolonged in hepatic impairment (up to 3.1 hours). Clinically, it corrects within 2–4 hours after infusion cessation.
Primarily hepatic (CYP450) metabolism; fecal (~65% as unchanged and metabolites) and renal (~22% with ~16% unchanged) elimination.
Primarily hepatobiliary (fecal excretion) ~65% as unchanged drug and metabolites; renal excretion ~22% (12% unchanged, 10% as metabolites). Minimal biliary excretion of unchanged drug.
Category C
Category C
Direct Thrombin Inhibitor
Direct Thrombin Inhibitor
"Argatroban may increase the anticoagulant activities of Loxoprofen."